PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement
2024

Study of LB-102: A New Antipsychotic Drug

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): Dean F. Wong, Ganesh B. Chand, Nicole Caito, Anna Eramo, Vincent T. Grattan, Mark S. Hixon, Ginger Nicol, Erin Lessie, Zachary Prensky, Hiroto Kuwabara, Lucy Tian, Ines Valenta, Thomas H. Schindler, Gerhard GrĂ¼nder, Andrew R. Vaino

Primary Institution: Washington University in Saint Louis

Hypothesis

Does LB-102 provide effective dopamine receptor occupancy in healthy volunteers?

Conclusion

LB-102 demonstrated prolonged dopamine receptor occupancy, suggesting it could be effective in treating schizophrenia.

Supporting Evidence

  • LB-102 provided consistent dopamine receptor occupancy in the desired range over 24 hours.
  • The study showed that maximum dopamine receptor occupancy lagged behind maximum plasma concentration.
  • LB-102 was generally safe and well-tolerated at all doses.
  • Results informed dosing for a subsequent Phase 2 clinical study in schizophrenia patients.

Takeaway

LB-102 is a new medicine that helps the brain work better for people with schizophrenia, and it stays effective for a long time.

Methodology

The study used positron emission tomography (PET) to measure dopamine receptor occupancy in healthy volunteers after administering different doses of LB-102.

Limitations

The study had a small sample size and did not take statistical powering assumptions into account.

Participant Demographics

16 healthy volunteers (7 female, 9 male) aged 18 to 55 years with a BMI between 18 and 30 kg/m2.

Digital Object Identifier (DOI)

10.1038/s41386-024-01951-x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication